当前位置： SCI文献检索 > Targeted Oncology期刊下所有文献 > Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.

Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.

Abstract：

:Data regarding the expression of epidermal growth factor receptor (EGFR) in melanoma and its role in the tumor biology are conflicting. In BRAF V600-mutant melanomas, the expression of EGFR has been associated with acquired resistance to BRAF inhibitors. In this study, we assessed EGFR expression and downstream signaling activity in a panel of melanoma cell lines and we investigated the effects of the BRAF inhibitor vemurafenib on expression of EGFR and its downstream effectors in a subgroup of BRAF-mutant melanoma cells. Three out of 10 melanoma cell lines expressed EGFR. Downstream signaling via ERK and AKT was responsive to either stimulation by EGF or inhibition by erlotinib. Constitutive activation of ERK occurred in all the cell lines investigated whereas constitutive activation of AKT only in three cell lines. Constitutive activation of ERK and AKT was independent from EGFR expression. Vemurafenib did not affect EGFR expression in general, but it increased EGFR phosphorylation in the cell line SkMel5. Induced EGFR phosphorylation was sensitive to treatment with erlotinib. Vemurafenib efficiently blocked ERK activation in all the BRAF-mutant cell lines tested, whereas its effects on AKT activation were dissimilar in the different cell lines. Our data suggest that EGFR is functional but usually inactive in EGFR high-expressing cell lines. Basal EGFR expression unlikely represents a biomarker for predicting the sensitivity to vemurafenib in melanoma, but EGFR activation might represent a mechanism of vemurafenib resistance in a subset of melanoma cells.

journal_name

Target Oncol

journal_title

Targeted oncology

authors

Gross A,Niemetz-Rahn A,Nonnenmacher A,Tucholski J,Keilholz U,Fusi A

doi

10.1007/s11523-014-0318-9

subject

Has Abstract

pub_date

2015-03-01 00:00:00

pages

77-84

issue

1

eissn

1776-2596

issn

1776-260X

journal_volume

10

pub_type

杂志文章

相关文献

Targeted Oncology文献大全
  • Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.

    abstract：BACKGROUND:Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal toxicities, which may be influenced by pre-existing renal dysfunction. OBJECTIVE:The objective was t...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-015-0389-2

    authors： Chen Y,Rini BI,Motzer RJ,Dutcher JP,Rixe O,Wilding G,Stadler WM,Tarazi J,Garrett M,Pithavala YK

    更新日期：2016-04-01 00:00:00

  • Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy.

    abstract：BACKGROUND:In 2017, nivolumab monotherapy was shown to be effective as third- or later-line therapy in patients with advanced gastric or gastroesophageal junction cancer. OBJECTIVE:In this study, we investigated the relationship between the neutrophil-to-lymphocyte ratio (NLR) and the outcomes of nivolumab monotherapy...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00716-y

    authors： Yamada T,Hayashi T,Inokuchi Y,Hayashi K,Watanabe H,Komori K,Kano K,Shimoda Y,Fujikawa H,Shiozawa M,Morinaga S,Rino Y,Masuda M,Ogata T,Oshima T

    更新日期：2020-06-01 00:00:00

  • Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells.

    abstract：BACKGROUND:Hypovitaminosis D is associated with an adverse prognosis in colon cancer patients, possibly due to the effects of the vitamin on the immune system. Antibody-dependent cell-mediated cytotoxicity (ADCC) significantly contributes to the anti-tumor effects of monoclonal antibodies, including cetuximab, an epide...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-018-0586-x

    authors： Mortara L,Gariboldi MB,Bosi A,Bregni M,Pinotti G,Guasti L,Squizzato A,Noonan DM,Monti E,Campiotti L

    更新日期：2018-10-01 00:00:00

  • Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.

    abstract：:Atezolizumab (Tecentriq®), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-019-00686-w

    authors： Dhillon S,Syed YY

    更新日期：2019-12-01 00:00:00

  • A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

    abstract：:The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody fragments and a catalytic protein toxin allowing it to bind two CSC marke...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-013-0290-9

    authors： Waldron NN,Barsky SH,Dougherty PR,Vallera DA

    更新日期：2014-09-01 00:00:00

  • Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice.

    abstract：:The advent of imatinib mesilate, an oral target therapy, has dramatically changed the natural history of gastrointestinal stromal tumours (GISTs). This rare neoplasm has become the paradigm of targeted therapies in solid tumours, also introducing a home-based cure concept in oncology. However, it should be retained th...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-012-0221-1

    authors： Saponara M,Pantaleo MA,Nannini M,Biasco G

    更新日期：2012-12-01 00:00:00

  • Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.

    abstract：:Venetoclax (Venclyxto®; Venclexta®) is a first-in-class, oral, selective B cell lymphoma-2 (BCL-2) inhibitor. The drug is approved in numerous countries, including those of the EU and in the USA, for the treatment of adults with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL); the specific indication(s)...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-019-00673-1

    authors： Scott LJ

    更新日期：2019-10-01 00:00:00

  • Targeted therapies in thyroid cancer.

    abstract：:Differentiated thyroid carcinoma is the most frequent neoplasm of the endocrine system. Although thyroid cancer usually has an excellent prognosis, no therapeutic options are available for patients that develop metastases and are or became resistant to radioiodine therapy. The deeper knowledge of molecular aberrations...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-009-0124-y

    authors： Capdevila J,Perez-Garcia J,Obiols G,Tabernero J

    更新日期：2009-12-01 00:00:00

  • Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.

    abstract：BACKGROUND:Serum protein fraction (SPF) is a common parameter reflecting the nutritional and inflammatory status of the human body. However, its role in patients with cancer, particularly those treated with targeted agents, is unknown. OBJECTIVE:We conducted this study to explore the prognostic value of SPF in patient...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-019-00625-9

    authors： Chen X,Yao J,Liu L,Zheng W,Hu X,Zhu Y,Wang H,Guo J

    更新日期：2019-04-01 00:00:00

  • Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

    abstract：BACKGROUND:The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions. OBJECTIVE:We assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor ...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-018-0595-9

    authors： Tzeng A,Diaz-Montero CM,Rayman PA,Kim JS,Pavicic PG Jr,Finke JH,Barata PC,Lamenza M,Devonshire S,Schach K,Emamekhoo H,Ernstoff MS,Hoimes CJ,Rini BI,Garcia JA,Gilligan TD,Ornstein MC,Grivas P

    更新日期：2018-10-01 00:00:00

  • Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.

    abstract：:The ubiquitin (Ub)+proteasome proteolytic pathway is responsible for the selective degradation of the majority of nuclear and cytosolic proteins. The proteasome is a high molecular weight multicatalytic protease that serves as the catalytic core of the complex Ub-dependent protein degradation pathway and is an excitin...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-010-0165-2

    authors： Driscoll JJ,Dechowdhury R

    更新日期：2010-12-01 00:00:00

  • Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.

    abstract：BACKGROUND:Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are re...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00703-3

    authors： Huang D,Zhang F,Tao H,Zhang S,Ma J,Wang J,Liu Z,Cui P,Chen S,Huang Z,Wu Z,Zhao L,Hu Y

    更新日期：2020-02-01 00:00:00

  • Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.

    abstract：:We aimed to assess the prognostic role of pretreatment neutrophilia, lymphocytopenia, and neutrophil to lymphocyte ratio (NLR) in patients treated with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGFR-TKIs) for late relapsing (>5 years) metastatic renal cell carcinoma (mRCC). Data were collected fr...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-014-0356-3

    authors： Santoni M,Buti S,Conti A,Porta C,Procopio G,Sternberg CN,Bracarda S,Basso U,De Giorgi U,Rizzo M,Derosa L,Ortega C,Massari F,Milella M,Bersanelli M,Cerbone L,Muzzonigro G,Burattini L,Montironi R,Santini D,Cascinu S

    更新日期：2015-12-01 00:00:00

  • The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.

    abstract：OBJECTIVE:To determine the efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in molecularly selected patients with advanced non-small cell lung cancer (NSCLC), we performed this pooled analysis. METHOD:Randomized trials of EGFR-TKIs as treatment for advanced NSCLC wer...

    journal_title：Targeted oncology

    pub_type： 杂志文章,meta分析,收录出版

    doi：10.1007/s11523-015-0376-7

    authors： Liu J,Sheng Z,Zhang Y,Li G

    更新日期：2016-02-01 00:00:00

  • Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.

    abstract：:ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the United States, Europ...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-019-00675-z

    authors： Kolberg HC,Colleoni M,Santi P,Demetriou GS,Segui-Palmer MA,Fujiwara Y,Hurvitz SA,Hanes V

    更新日期：2019-12-01 00:00:00

  • Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.

    abstract：BACKGROUND:The prognosis of patients with advanced pancreatic cancer is dismal, and there is a need for novel and effective treatments. OBJECTIVES:Tο determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a novel gemcitabine (G) and temsirolimus (T) combination (phase I) and estimate the 6-m...

    journal_title：Targeted oncology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11523-018-0605-y

    authors： Karavasilis V,Samantas E,Koliou GA,Kalogera-Fountzila A,Pentheroudakis G,Varthalitis I,Linardou H,Rallis G,Skondra M,Papadopoulos G,Papatsibas G,Sgouros J,Goudopoulou A,Kalogeras KT,Dervenis C,Pectasides D,Fountzilas G

    更新日期：2018-12-01 00:00:00

  • Sorafenib: A Review in Hepatocellular Carcinoma.

    abstract：:Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall surviva...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-017-0484-7

    authors： Keating GM

    更新日期：2017-04-01 00:00:00

  • The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.

    abstract：:The influence of tumor infiltrating lymphocytes on tumor growth and response to therapy is becoming increasingly apparent. While much work has focused on the role of T cell responses in anti-tumor immunity, the role of B cells in solid tumors is much less understood. Tumor infiltrating B cells have been found in a var...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-017-0481-x

    authors： Flynn NJ,Somasundaram R,Arnold KM,Sims-Mourtada J

    更新日期：2017-04-01 00:00:00

  • Impact of biomarkers on non-small cell lung cancer treatment.

    abstract：:Chemotherapy represents the mainstay of non-small cell lung cancer (NSCLC) treatment, but response is usually observed in only one out of three patients. Massive efforts have been carried out to identify biomarkers that might help clinicians to choose appropriate drugs, by identifying potentially sensitive subjects an...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-010-0132-y

    authors： Toschi L,Cappuzzo F

    更新日期：2010-03-01 00:00:00

  • Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.

    abstract：BACKGROUND:The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. OBJECTIVE:This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with carboplatin alone or paclitaxel plus carboplatin in Asian patients wi...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00701-5

    authors： Kato H,de Souza P,Kim SW,Lickliter JD,Naito Y,Park K,Kumar S,Mugundu GM,Bang YJ

    更新日期：2020-02-01 00:00:00

  • Renal Toxicities of Targeted Therapies.

    abstract：:With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal tox...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-015-0368-7

    authors： Abbas A,Mirza MM,Ganti AK,Tendulkar K

    更新日期：2015-12-01 00:00:00

  • Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.

    abstract：:Several angiogenesis inhibitors have been approved for commercial use and many additional agents are under development for the treatment of various malignancies. Cardiovascular toxicities have been increasingly recognized as effects of this entire class of new anticancer therapeutics. There is a limited but growing un...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-009-0106-0

    authors： Snider KL,Maitland ML

    更新日期：2009-04-01 00:00:00

  • Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX).

    abstract：BACKGROUND:Golgi phosphoprotein 2 (GOLPH2) has been shown to be involved in chronic inflammatory processes and carcinogenesis. GOLPH2 is prominently overexpressed in hepatocellular carcinoma, melanoma, glioblastoma, prostate, lung, and colorectal cancer. With a low and tightly regulated expression in non-malignant tiss...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-019-00667-z

    authors： Liewen H,Markuly N,Läubli H,Liu Y,Matter MS,Liewen N,Renner C,Zippelius A,Stenner F

    更新日期：2019-10-01 00:00:00

  • QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review.

    abstract：:In anticancer drug development, there has been increasing consideration for the potential of a compound to cause adverse electrocardiographic changes, especially QT interval prolongation, which can be associated with risk of torsades de pointes and sudden death. Irrespective of overt clinical toxicities, QTc assessmen...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-014-0325-x

    authors： Locatelli M,Criscitiello C,Esposito A,Minchella I,Goldhirsch A,Cipolla C,Curigliano G

    更新日期：2015-03-01 00:00:00

  • Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.

    abstract：:Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib. Retrospective studies documented the same bene...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-010-0163-4

    authors： Rossi D,Dennetta D,Ugolini M,Catalano V,Alessandroni P,Giordani P,Baldelli AM,Casadei V,Graziano F,Luzi Fedeli S

    更新日期：2010-12-01 00:00:00

  • Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.

    abstract：:Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) catalyze the first rate-limiting step in the oxidative metabolism of compounds containing indole rings, including the transformation of the essential amino acid L-tryptophan to N-formyl-L-kynurenine. Through direct and indirect means, IDO exerts bo...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-017-0547-9

    authors： Davar D,Bahary N

    更新日期：2018-04-01 00:00:00

  • Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

    abstract：BACKGROUND:Sunitinib (S) is a multi-targeted tyrosine kinase inhibitor. It is synergistic with chemotherapy in preclinical models. We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal jun...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-019-00692-y

    authors： Mukherjee S,Fountzilas C,Boland PM,Gosain R,Attwood K,Tan W,Khushalani N,Iyer R

    更新日期：2020-02-01 00:00:00

  • Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.

    abstract：:Obinutuzumab (Gazyva®, Gazyvaro®) is a recombinant, monoclonal, humanized and glycoengineered, type II, anti-CD20, IgG1 antibody. It has recently been granted an additional indication for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. In the...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-017-0485-6

    authors： Dhillon S

    更新日期：2017-04-01 00:00:00

  • Hyperbaric oxygen therapy and cancer--a review.

    abstract：:Hypoxia is a critical hallmark of solid tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen (HBO) treatment has for centuries been used to improve or cure disorders involving hypoxia and ischemia, by enhancing the amount of dissolved oxygen in the plasma a...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-012-0233-x

    authors： Moen I,Stuhr LE

    更新日期：2012-12-01 00:00:00

  • Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.

    abstract：:Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tu...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-012-0216-y

    authors： Faivre S,Ronot M,Dreyer C,Serrate C,Hentic O,Bouattour M,Bruno O,Couvelard A,Vilgrain V,Raymond E

    更新日期：2012-06-01 00:00:00